BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 24, 2011
 |  BioCentury  |  Emerging Company Profile

Durin: Tracking AD autoantibodies

Durin developing autoantibody blood test for early detection of Alzheimer's

Molecular diagnosis of Alzheimer's disease is limited to the detection of beta amyloid and tau in the brain or cerebrospinal fluid, which does not provide early diagnosis and can be onerous to perform. Durin Technologies Inc. believes its blood-based autoantibody signature will be able to diagnose AD sooner and allow for earlier treatment.

As people age, the blood-brain barrier (BBB) breaks down, and proteins like beta amyloid and autoantibodies can enter the brain. Beta amyloid binds to the autoantibodies, which are internalized by neurons. The autoantibodies are metabolized and excreted, but beta amyloid builds up, leading to neuron death and the formation of plaques.

Guidelines issued in 2010 by the Alzheimer's Association recommend molecular detection of beta amyloid 42, a 42-amino acid fragment of the membrane-bound amyloid precursor protein (APP), along with cognitive symptoms, to help diagnose AD (see BioCentury, Aug. 16, 2010).

The guidelines also recommend directly detecting amyloid plaques using positron emission tomography (PET)...

Read the full 784 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >